Plasma Glutathione Levels Decreased with Cognitive Decline among People with Mild Cognitive Impairment (MCI): A Two-Year Prospective Study

Glutathione (GSH) is a major endogenous antioxidant. Several studies have shown GSH redox imbalance and altered GSH levels in Alzheimer’s disease (AD) patients. Early detection is crucial for the outcome of AD. However, whether GSH can serve as a biomarker during the very early-phase of AD, such as...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chieh-Hsin Lin, Hsien-Yuan Lane
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	glutathione (GSH) mild cognitive impairment (MCI) Alzheimer’s disease (AD) cognitive function biomarker Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/fec705f00af9448caca8004e0ceed222
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fec705f00af9448caca8004e0ceed222
record_format	dspace
spelling	oai:doaj.org-article:fec705f00af9448caca8004e0ceed2222021-11-25T16:29:39ZPlasma Glutathione Levels Decreased with Cognitive Decline among People with Mild Cognitive Impairment (MCI): A Two-Year Prospective Study10.3390/antiox101118392076-3921https://doaj.org/article/fec705f00af9448caca8004e0ceed2222021-11-01T00:00:00Zhttps://www.mdpi.com/2076-3921/10/11/1839https://doaj.org/toc/2076-3921Glutathione (GSH) is a major endogenous antioxidant. Several studies have shown GSH redox imbalance and altered GSH levels in Alzheimer’s disease (AD) patients. Early detection is crucial for the outcome of AD. However, whether GSH can serve as a biomarker during the very early-phase of AD, such as mild cognitive impairment (MCI), remains unknown. The current prospective study aimed to examine the longitudinal change in plasma GSH concentration and its influence on cognitive decline in MCI. Overall, 49 patients with MCI and 16 healthy individuals were recruited. Plasma GSH levels and cognitive function, measured by the Mini-Mental Status Examination (MMSE) and Alzheimer’s disease assessment scale-cognitive subscale (ADAS-cog), were monitored every 6 months. We employed multiple regressions to examine the role of GSH level in cognitive decline in the 2 years period. The MCI patients showed significant decline in plasma GSH levels and cognitive function from baseline to endpoint (month 24). In comparison, the healthy individuals’ GSH concentration and cognitive function did not change significantly. Further, both GSH level at baseline and GSH level change from baseline to endpoint significantly influenced cognitive decline among the MCI patients. To our knowledge, this is the first study to demonstrate that both plasma GSH levels and cognitive function declined 2 years later among the MCI patients in a prospective manner. If replicated by future studies, blood GSH concentration may be regarded as a biomarker for monitoring cognitive change in MCI.Chieh-Hsin LinHsien-Yuan LaneMDPI AGarticleglutathione (GSH)mild cognitive impairment (MCI)Alzheimer’s disease (AD)cognitive functionbiomarkerTherapeutics. PharmacologyRM1-950ENAntioxidants, Vol 10, Iss 1839, p 1839 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	glutathione (GSH) mild cognitive impairment (MCI) Alzheimer’s disease (AD) cognitive function biomarker Therapeutics. Pharmacology RM1-950
spellingShingle	glutathione (GSH) mild cognitive impairment (MCI) Alzheimer’s disease (AD) cognitive function biomarker Therapeutics. Pharmacology RM1-950 Chieh-Hsin Lin Hsien-Yuan Lane Plasma Glutathione Levels Decreased with Cognitive Decline among People with Mild Cognitive Impairment (MCI): A Two-Year Prospective Study
description	Glutathione (GSH) is a major endogenous antioxidant. Several studies have shown GSH redox imbalance and altered GSH levels in Alzheimer’s disease (AD) patients. Early detection is crucial for the outcome of AD. However, whether GSH can serve as a biomarker during the very early-phase of AD, such as mild cognitive impairment (MCI), remains unknown. The current prospective study aimed to examine the longitudinal change in plasma GSH concentration and its influence on cognitive decline in MCI. Overall, 49 patients with MCI and 16 healthy individuals were recruited. Plasma GSH levels and cognitive function, measured by the Mini-Mental Status Examination (MMSE) and Alzheimer’s disease assessment scale-cognitive subscale (ADAS-cog), were monitored every 6 months. We employed multiple regressions to examine the role of GSH level in cognitive decline in the 2 years period. The MCI patients showed significant decline in plasma GSH levels and cognitive function from baseline to endpoint (month 24). In comparison, the healthy individuals’ GSH concentration and cognitive function did not change significantly. Further, both GSH level at baseline and GSH level change from baseline to endpoint significantly influenced cognitive decline among the MCI patients. To our knowledge, this is the first study to demonstrate that both plasma GSH levels and cognitive function declined 2 years later among the MCI patients in a prospective manner. If replicated by future studies, blood GSH concentration may be regarded as a biomarker for monitoring cognitive change in MCI.
format	article
author	Chieh-Hsin Lin Hsien-Yuan Lane
author_facet	Chieh-Hsin Lin Hsien-Yuan Lane
author_sort	Chieh-Hsin Lin
title	Plasma Glutathione Levels Decreased with Cognitive Decline among People with Mild Cognitive Impairment (MCI): A Two-Year Prospective Study
title_short	Plasma Glutathione Levels Decreased with Cognitive Decline among People with Mild Cognitive Impairment (MCI): A Two-Year Prospective Study
title_full	Plasma Glutathione Levels Decreased with Cognitive Decline among People with Mild Cognitive Impairment (MCI): A Two-Year Prospective Study
title_fullStr	Plasma Glutathione Levels Decreased with Cognitive Decline among People with Mild Cognitive Impairment (MCI): A Two-Year Prospective Study
title_full_unstemmed	Plasma Glutathione Levels Decreased with Cognitive Decline among People with Mild Cognitive Impairment (MCI): A Two-Year Prospective Study
title_sort	plasma glutathione levels decreased with cognitive decline among people with mild cognitive impairment (mci): a two-year prospective study
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/fec705f00af9448caca8004e0ceed222
work_keys_str_mv	AT chiehhsinlin plasmaglutathionelevelsdecreasedwithcognitivedeclineamongpeoplewithmildcognitiveimpairmentmciatwoyearprospectivestudy AT hsienyuanlane plasmaglutathionelevelsdecreasedwithcognitivedeclineamongpeoplewithmildcognitiveimpairmentmciatwoyearprospectivestudy
_version_	1718413177353404416

Plasma Glutathione Levels Decreased with Cognitive Decline among People with Mild Cognitive Impairment (MCI): A Two-Year Prospective Study

Ejemplares similares